NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025

17.09.25 14:12 Uhr

PHILADELPHIA, Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo.

A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto/Berger Montague)

Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025(the "Class Period"), may, no later than September 30, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

On July 29, 2025, Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for both Wegovy® and Ozempic®.

In reaction, Novo's stock price plunged from $69.00 to $53.94 per share, a one-day decline of more than 21%.

If you are a Novo investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-as-nyse-nvo-class-action-deadline-approaching-berger-montague-advises-investors-to-inquire-about-a-securities-fraud-class-action-by-september-30-2025-302558620.html

SOURCE Berger Montague

Nachrichten zu Novo Nordisk (spons. ADRs)

Wer­bung

Analysen zu Novo Nordisk (spons. ADRs)

DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
15.10.2012Novo Nordisk kaufenEuro am Sonntag
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
DatumRatingAnalyst
15.10.2012Novo Nordisk kaufenEuro am Sonntag
30.04.2012Novo Nordisk buyCitigroup Corp.
09.07.2007Novo Nordisk kaufen und liegenlassenGlobal Biotech Investing
14.12.2006Update Novo Nordisk A/S (Spons. ADRS): BuyCitigroup
08.12.2005Update Novo Nordisk A/S (Spons. ADRS): OutperformBear Stearns
DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
18.05.2012Novo Nordisk equal-weightMorgan Stanley
DatumRatingAnalyst
30.05.2012Novo Nordisk underperformCheuvreux SA
22.03.2012Novo Nordisk sellDeutsche Bank AG
22.03.2012Novo Nordisk reduceNomura
21.02.2012Novo Nordisk reduceNomura
30.01.2012Novo Nordisk reduceNomura

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novo Nordisk (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen